Global collaboration Medicines Discovery Catapult operates as a global centre with international collaborations across 15 countries and 4 continents, presenting a sales opportunity to partner with multinational biotech and pharma developers seeking distributed translational capabilities and cross-border regulatory support.

End-to-end capability MDC offers a full-stack accelerator spanning radiopharmaceuticals, biomarkers, in vitro biology, and regulatory-aligned R&D consultancy, enabling potential clients to de-risk complex programs under one partner and reducing the need for multiple vendor engagements.

Investor-grade data Position MDC as the provider of high-quality, investor-grade data and expert project management to de-risk programs and accelerate talks with clinical partners, investors, and grant bodies, aligning with customer funding milestones.

Commercial healthcare impact With a stated mission to accelerate discovery and bring medicines to patients faster, target pharma and biotech firms aiming to shorten development timelines, especially for translational imaging, target engagement validation, and Phase 0 readiness.

Growing ecosystem Recent partnerships and engagements with government and industry initiatives (DfT TRIG, academic collaborations, Connected Places Catapult networks) signal MDC’s access to funding channels and joint ventures, offering sales angles around co-funded projects and strategic consortia participation.